false
0001551152
Common Stock, $0.01 Par Value
ABBV
0001551152
2024-02-12
2024-02-12
0001551152
us-gaap:CommonStockMember
exch:XNYS
2024-02-12
2024-02-12
0001551152
exch:XCHI
us-gaap:CommonStockMember
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2024-02-12
2024-02-12
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2024-02-12
2024-02-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 12, 2024
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other jurisdiction of incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Former name or former address,
if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange Chicago Stock Exchange |
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
Item 7.01 | Regulation FD Disclosure |
On February 12, 2024, AbbVie Inc. (the “Company”)
issued a press release announcing the completion of its acquisition of ImmunoGen, Inc. The press release is attached hereto as Exhibit 99.1
and incorporated by reference herein.
The information in this Item 7.01, including the exhibit referenced
herein and attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any Company filing under the Securities Act
of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Forward-Looking Statements
Some statements in this Current Report on Form 8-K are, or may
be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,”
“expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs,
generally identify forward-looking statements. The Company cautions that these forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties
include, but are not limited to, risks related to the ability to realize the anticipated benefits of the ImmunoGen acquisition on the
anticipated timeframe or at all, risks that the cost to consummate the ImmunoGen acquisition or to obtain the anticipated benefits of
the acquisition could be greater than expected, the risk that the ImmunoGen business will not be integrated successfully, disruption from
the ImmunoGen acquisition making it more difficult to maintain business and operational relationships, the diversion of management’s
attention from ongoing business operations and opportunities, negative effects of the consummation of the acquisition on business or employee
relationships or the market price of AbbVie’s common stock and/or operating results, significant transaction costs, the assumption
of unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition or ImmunoGen’s business, challenges
to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation
or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect the Company’s operations is set forth in Item 1A, “Risk Factors,”
of the Company’s 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission (the “SEC”),
as updated by its subsequent Quarterly Reports on Form 10-Q and in other documents that the Company subsequently files with the SEC
that update, supplement or supersede such information. The Company undertakes no obligation, and specifically declines, to release publicly
any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Item 9.01 |
Financial Statements and Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABBVIE INC. |
|
Date: February 12, 2024 |
By: |
/s/ Scott T. Reents |
|
|
Scott T. Reents |
|
|
Executive Vice President, |
|
|
Chief Financial Officer |
Exhibit 99.1
PRESS RELEASE
AbbVie Completes Acquisition of ImmunoGen
| - | Adds
flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx)
for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to
AbbVie’s portfolio |
| - | ImmunoGen's
pipeline complements AbbVie's existing oncology pipeline, with potential to be transformative
across multiple solid tumors and hematologic malignancies |
| - | ImmunoGen's
late-stage development programs for ELAHERE provide opportunity to expand into earlier lines
of therapy and additional patient populations |
| - | AbbVie
reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$11.25
which now includes a $0.42 per share dilutive impact related to the ImmunoGen acquisition
and the pending Cerevel Therapeutics acquisition |
| - | AbbVie
updates previously issued 2024 first-quarter adjusted diluted EPS guidance range from $2.30-$2.34
to $2.26-$2.30 which now includes a $0.04 per share dilutive impact related to the ImmunoGen
acquisition |
NORTH CHICAGO, Ill., February
12, 2024 – AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN). With the
completion of the acquisition, ImmunoGen is now part of AbbVie.
“Together with ImmunoGen,
we have the potential to continue redefining the standard of care for those living with cancer,” said Robert A. Michael, president
and chief operating officer, AbbVie. “The addition of ImmunoGen’s treatment for ovarian cancer will accelerate our ability
to help patients today, expand our oncology pipeline and drive long-term revenue growth well into the next decade. I want to thank ImmunoGen
for their efforts to advance science for patients and we look forward to welcoming our new colleagues to AbbVie.”
ELAHERE® (mirvetuximab
soravtansine-gynx), is the first and only ADC approved by the U.S. Food and Drug Administration (FDA) in ovarian cancer. The FDA granted
accelerated approval for ELAHERE in FRα positive platinum-resistant ovarian cancer patients based on response data. Results from
a confirmatory trial currently under review by the FDA show that ELAHERE is the first targeted agent to offer a survival benefit in platinum-resistant
ovarian cancer patients, with label expansion opportunities across larger segments of the ovarian cancer market.
ImmunoGen’s follow-on
pipeline of ADCs further builds on AbbVie’s existing solid tumor pipeline of novel targeted therapies and next-generation immuno-oncology
assets, which have the potential to create new treatment possibilities across multiple solid tumors and hematologic malignancies. Through
focused R&D efforts, AbbVie has developed novel ADC technology and has unique strengths in antibody engineering, drug linker chemistry
and toxin research. AbbVie and ImmunoGen’s combined capabilities represent an opportunity to deliver potentially transformative
ADC therapies to patients.
ImmunoGen's investigational
Phase 1 asset, IMGN-151, is a next-generation FRα ADC for ovarian cancer with the potential for expansion into other solid tumor
indications.
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064 |
|
Pivekimab sunirine, currently
in Phase 2, is an investigational anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer,
which was granted FDA breakthrough therapy designation for the treatment of relapsed/refractory BPDCN.
For additional background on the acquisition,
please read the announcement press release here and view AbbVie’s investor presentation here.
Financial Terms
AbbVie has acquired all outstanding
ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to trade on the NASDAQ stock exchange
prior to market open on February 12, 2024. AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie’s diluted EPS
beginning in 2027 and significantly accretive over the long-term.
Full-Year 2024 Outlook
AbbVie is reaffirming its previously
issued 2024 full-year adjusted diluted EPS guidance range of $11.05-$11.25. This guidance now includes a $0.42 per share dilutive impact
related to the completed ImmunoGen acquisition, as well as the pending Cerevel Therapeutics acquisition, which is anticipated to close
in mid-2024. AbbVie’s 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be
incurred during 2024, as both cannot be reliably forecasted.
AbbVie is updating its previously
issued 2024 first-quarter adjusted diluted EPS guidance range from $2.30 - $2.34 to $2.26 - $2.30. This guidance now includes a $0.04
per share dilutive impact related to the ImmunoGen acquisition. AbbVie’s 2024 first-quarter adjusted diluted EPS guidance excludes
any impact from acquired IPR&D and milestones that may be incurred in the quarter, as both cannot be reliably forecasted.
About ELAHERE (mirvetuximab soravtansine-gynx)
ELAHERE (mirvetuximab soravtansine-gynx)
is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent
tubulin inhibitor designed to kill the targeted cancer cells.
ELAHERE is indicated for the
treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or
primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an
FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued
approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The prescribing information
includes a boxed warning. ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia,
eye pain, and uveitis. Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other
cycle for the first 8 cycles, and as clinically indicated. Administer prophylactic artificial tears and ophthalmic topical steroids.
Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose. Discontinue ELAHERE for Grade 4 ocular
toxicities.
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064 |
|
Serious adverse reactions occurred
in 31% of patients. The most common (≥2%) serious adverse reactions were intestinal obstruction (8%), ascites (4%), infection (3%),
and pleural effusion (3%). Fatal adverse reactions occurred in 2% of patients, including small intestinal obstruction (1%) and pneumonitis
(1%).The most common (≥20%) adverse reactions, including laboratory abnormalities, were vision impairment, fatigue, increased aspartate
aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy,
diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased
neutrophils, and decreased hemoglobin.
Please see full Prescribing Information,
including Boxed Warning for ELAHERE.
About AbbVie in Oncology
At AbbVie, we are committed to transforming
standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer
types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough
medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread
and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients
obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We
strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience,
and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit
us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news
release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The
words "believe," "expect," "anticipate," "project" and similar expressions and uses of future
or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking
statements. Such risks and uncertainties include, but are not limited to, risks related to the ability to realize the anticipated benefits
of the ImmunoGen acquisition on the anticipated timeframe or at all, risks that the cost to consummate the ImmunoGen acquisition or to
obtain the anticipated benefits of the acquisition could be greater than expected, the risk that the ImmunoGen business will not be integrated
successfully, disruption from the ImmunoGen acquisition making it more difficult to maintain business and operational relationships,
the diversion of management’s attention from ongoing business operations and opportunities, negative effects of the consummation
of the acquisition on business or employee relationships or the market price of AbbVie’s common stock and/or operating results,
significant transaction costs, the assumption of unknown
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064 |
|
liabilities, the risk of litigation
and/or regulatory actions related to the acquisition or ImmunoGen’s business, challenges to intellectual property, competition
from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes
to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological
and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report
on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form
10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as
a result of subsequent events or developments, except as required by law.
###
Media: |
Investors: |
Gabrielle Tarbert |
Liz Shea |
(224) 244-0111 |
(847) 935-2211 |
gabrielle.tarbert@abbvie.com |
liz.shea@abbvie.com |
AbbVie Inc. |
+1 (847) 938-9190 |
1 North Waukegan Road |
abbvie.com |
North Chicago, IL 60064 |
|
v3.24.0.1
Cover
|
Feb. 12, 2024 |
Document Information [Line Items] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 12, 2024
|
Entity File Number |
001-35565
|
Entity Registrant Name |
ABBVIE INC.
|
Entity Central Index Key |
0001551152
|
Entity Tax Identification Number |
32-0375147
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1 North Waukegan Road
|
Entity Address, City or Town |
North Chicago
|
Entity Address, State or Province |
IL
|
Entity Address, Postal Zip Code |
60064-6400
|
City Area Code |
847
|
Local Phone Number |
932-7900
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
false
|
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, $0.01 Par Value
|
Trading Symbol |
ABBV
|
Security Exchange Name |
NYSE
|
Common Stock [Member] | NYSE CHICAGO, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
Common Stock, $0.01 Par Value
|
Trading Symbol |
ABBV
|
Security Exchange Name |
CHX
|
Senior Notes 1.375 Percent due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.375% Senior Notes due 2024
|
Trading Symbol |
ABBV24
|
Security Exchange Name |
NYSE
|
Senior Notes 1.250 Percent due 2024 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.250% Senior Notes due 2024
|
Trading Symbol |
ABBV24B
|
Security Exchange Name |
NYSE
|
Senior Notes 0.750 Percent due 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
0.750% Senior Notes due 2027
|
Trading Symbol |
ABBV27
|
Security Exchange Name |
NYSE
|
Senior Notes 2.125 Percent due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.125% Senior Notes due 2028
|
Trading Symbol |
ABBV28
|
Security Exchange Name |
NYSE
|
Senior Notes 2.625 Percent due 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.625% Senior Notes due 2028
|
Trading Symbol |
ABBV28B
|
Security Exchange Name |
NYSE
|
Senior Notes 2.125 Percent due 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
2.125% Senior Notes due 2029
|
Trading Symbol |
ABBV29
|
Security Exchange Name |
NYSE
|
Senior Notes 1.250 Percent due 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member] |
|
Document Information [Line Items] |
|
Title of 12(b) Security |
1.250% Senior Notes due 2031
|
Trading Symbol |
ABBV31
|
Security Exchange Name |
NYSE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_EntityListingsExchangeAxis=exch_XNYS |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_EntityListingsExchangeAxis=exch_XCHI |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.375Percentdue2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2024Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes0.750Percentdue2027Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2028Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.625Percentdue2028Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2029Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2031Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024